Compare Global X Copper Miners ETF (COPX) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Copper Miners ETF vs Moderna, Inc. — how do they compare? Global X Copper Miners ETF trades at $89.4, while Moderna, Inc. trades at $61.75 (market cap $24.18B). The key difference: Global X Copper Miners ETF is trading nearer its 52-week high, Moderna, Inc. nearer its low. Which is the better fit depends on your goals.
| COPX | MRNA | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $95.70 | $81.80 |
52-Week Low | $46.08 | $22.36 |
Market Cap | — | $24.18B |
Enterprise Value | — | $20.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
COPX, the Global X Copper Miners ETF, trades at $89.43, down slightly by 0.09% today. The technical outlook is bullish based on moving averages, but oscillators signal caution with RSI levels indicating overbought conditions. Recent news highlights institutional accumulation, with 180 Wealth Advisors increasing its stake by 28.1% in Q2 2026 (SEC filing, August 6, 2026). The ETF is positioned to benefit from copper demand driven by AI infrastructure and electrification trends.
The investment case for COPX hinges on structural copper demand growth from AI data centers and green energy, though it faces risks from commodity price volatility and mining supply constraints. Analysts view the recent pullback as a buying opportunity, citing operational leverage to copper prices. Key risks include cyclical mining downturns and execution challenges among constituent companies.
Moderna (MRNA) trades at $59.81, up 1.08% today, with a bullish technical signal from moving averages and recent FDA approval for its mRNA flu vaccine mFLUSIVA. Despite beating Q2 2026 EPS estimates, revenue has declined from pandemic peaks, with a net income margin of -142.58% in 2026. The stock faces resistance near $61-$63, while support lies at $56-$59.
Outlook remains mixed; pipeline advancements in flu, Ebola, and oncology offer growth potential, but persistent losses and high valuation ratios pose risks. Analyst consensus is cautious with a $54.33 price target below current levels, reflecting concerns over profitability amid transitioning business focus.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Global X Copper Miners ETF
COPX tracks the Solactive Global Copper Miners Total Return Index, providing broad exposure to companies worldwide involved in copper mining, refining, and exploration. It serves as an equity-based alternative to copper futures, offering a leveraged play on copper demand driven by global infrastructure and the clean energy transition.
Read more on COPX →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
